Cristina Suarez
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 133 publications
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.
Journal: The New England journal of medicine
Published: July 01, 2026
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.
Journal: Tumori
Published: May 04, 2026
Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Journal: Cancer treatment and research communications
Published: May 03, 2026
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: March 23, 2026
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.
Journal: Frontiers in oncology
Published: March 10, 2026
Immunosuppression with ruxolitinib and abatacept in immune checkpoint inhibitor-associated myocarditis: a temporal cohort comparison.
Journal: Revista espanola de cardiologia (English ed.)
Published: March 04, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 21, 2026
Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.
Journal: European urology
Published: February 13, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: January 16, 2026
Last Updated: 09/26/2026